Background
Phase 3 CRISTALLO, primary analysis. Fit, previously untreated CLL (CIRS ≤6, CrCl ≥70 mL/min) without del(17p)/TP53 mutation, randomized 1:1; 80 received fixed-duration venetoclax-obinutuzumab (VenO), 86 FCR/BR chemoimmunotherapy. First registrational-style head-to-head of VenO vs CIT in FIT patients.
Results
Interventions and follow up: Arm A: fixed-duration venetoclax + obinutuzumab (obinutuzumab debulking then venetoclax ramp-up)
Arm B: FCR (fludarabine-cyclophosphamide-rituximab) or BR (bendamustine-rituximab) per investigator
Primary endpoint: uMRD (10⁻⁴) in peripheral blood by NGS at month 15
mFollow up: NR (data cutoff 19 Mar 2024; PFS interim immature)
Results: uMRD 10⁻⁴ PB, month 15: 81.3% vs 54.7% (P=.0004) — primary endpoint met
uMRD 10⁻⁶ PB, month 15: 65.0% vs 25.6%
uMRD PB + BM at EOT: higher with VenO (rates favor VenO)
PFS: NR (immature; progression/death events 7 vs 13)
Arm B: FCR (fludarabine-cyclophosphamide-rituximab) or BR (bendamustine-rituximab) per investigator
Primary endpoint: uMRD (10⁻⁴) in peripheral blood by NGS at month 15
mFollow up: NR (data cutoff 19 Mar 2024; PFS interim immature)
Results: uMRD 10⁻⁴ PB, month 15: 81.3% vs 54.7% (P=.0004) — primary endpoint met
uMRD 10⁻⁶ PB, month 15: 65.0% vs 25.6%
uMRD PB + BM at EOT: higher with VenO (rates favor VenO)
PFS: NR (immature; progression/death events 7 vs 13)
Adverse events
Overall: consistent with known profiles of each regimen
TLS: no clinical TLS with VenO; no patient remained high-risk for TLS after obinutuzumab debulking
Grade ≥3 rates: NR in abstract
TLS: no clinical TLS with VenO; no patient remained high-risk for TLS after obinutuzumab debulking
Grade ≥3 rates: NR in abstract
Conclusions
Fixed-duration VenO achieved markedly deeper MRD responses than FCR/BR in fit untreated CLL, confirming and extending GAIA-CLL13. Further evidence that chemoimmunotherapy has no remaining niche in first-line CLL, including fit patients.
Key Limitations
Small trial (~166 treated); uMRD was the sole primary endpoint (surrogate) — accompanying Blood commentary (Cuneo & Ghia) debates when MRD truly matters in CLL. PFS/OS immature. del(17p)/TP53-mutated patients excluded. Sponsor-run (Genentech/Roche).
Clinical Context
VenO is already FDA/EMA-approved for 1L CLL (CLL14) and NCCN/ESMO-preferred; GAIA-CLL13 had shown superiority over CIT in fit patients without formal regulatory intent. CRISTALLO supplies confirmatory randomized data in fit patients, closing the door on FCR/BR.